Brains from 12 patients dying with a clinical diagnosis of frontal lobe dementia have been examined at post mortem.
In the not too distant past it was widely accepted that patients with cerebral atrophy could be confidently assumed to have Alzheimer's disease (AD) once cerebrovascular disease, trauma, and alcohol had been excluded, particularly during the presenium. However, it is now becoming increasingly recognised that certain non-Alzheimer forms of cerebral atrophy are more common than has been generally supposed and these may make a significant proportional contribution to all cases of dementia. In several surveys -3 their prevalence, compared with AD, has been estimated as 1:5, 1:8, or 1: 1 1 respectively. One such condition, clinically termned frontal lobe dementia45 or dementia of frontal lobe type (DFT)I presents typically with behavioural disturbances that lead to mutism and dementia. In about half of patients affected by DFT, a family history of a similar disorder seems to be present6; the pattern of inheritance being suggestive of the action of an autosomally dominant gene. Neuropathological descriptions of the brains of patients dying with DFT, however, remain scant. 24 The nosological and pathological relationships between DFT and Pick's disease and between DFT and other neurodegenerative disorders such as motor neuron disease (MND) with dementia7 8 and progressive aphasia9, remain uncertain. We present the neuropathological findings in the brains of 12 consecutive patients dying with a clinical history compatible with that of DFT.16 Materials and methods Brains were obtained at necropsy from 12 patients with a clinical diagnosis of DFT (see Neary et all for criteria and tables 1 and 2 for relevant demographic and clinical details). Brains were fixed, by immersion in 10% neutral formalin, for three to four weeks, then cut coronally into 2 cm slices. In some patients the right hemisphere was frozen for neurochemical analysis and in these only the left hemisphere, cerebellum, and brainstem were fixed for histology. From the fixed tissue, blocks were cut from all major cortical and non-cortical regions, processed routinely into paraffin wax, and serially sectioned at 5 ,um thickness. Certain sections were stained using conventional neurohistological methods including Palmgren silver stain for neurofibrillary tangles'0 and methenamine silver stain for amyloid (fl/A4) protein." 12 Other sections were stained immunohistochemically using a conventional avidin-biotin-peroxidase method'2 and employing primary antibodies Anti-tau and anti-ubiquitin immunohistochemistry showed widely differing patterns of staining, failing to reveal changes common to all, or even most, patients (table 5) with distinctive changes being demonstrated only in patients 6, 7, and 12. In patient 6 most surviving nerve cells within layer II of the frontal cortex, anterior temporal cortex, and entorhinal cortex displayed a strong anti-tau immunoreactivity; many nerve cells in layers III and V also showed this change. The taustaining appeared mostly diffuse and granular though sometimes well defined inclusions were seen (fig 3d) . Many of the tau positive cells and inclusions were also detected, though less strongly, with anti-ubiquitin. The white matter showed a pronounced granularity with anti-ubiquitin but not with anti-tau. This granularity of white matter staining with anti-ubiquitin is seen in other neurodegenerative diseases (for example, Alzheimer's disease, Mann unpublished observations) and increases with age in non-demented individuals14; it may represent a non-specific phenomenon (in disease terms) which is related to axonal loss or degeneration. These kinds of cortical change were less prominent within anterior parietal and posterior temporal regions, being absent in posterior parietal and occipital cortices. In the hippocampus many granular neurons of the dentate gyrus (fig 3c) and pyramidal neurons within areas CAI and subiculum showed strong anti-tau immunoreactivity that was again granular in nature with clearly defined inclusions only occasionally seen. These same cell types were also stained, but again less strongly, using anti-ubiquitin. In the amygdala and corpus striatum occasional cells were stained with anti-tau (but not anti-ubiquitin), in a diffuse and granular manner without formation of inclusions. Similar, though less extensive, changes to these were seen in patient 7 (table 5) .
In patient 12 a moderate number of nerve cells within frontal and anterior temporal cortex showed a strong reaction with anti-ubiquitin with staining being either diffusely granular or occasionally present as well defined rounded inclusions (fig 5c) . Much particulate material was present within the neuropil often with a "thread"-like appearance (fig 5d) . Anti-tau immunostaining revealed a similar though much less intense pattern of staining. Much granular material was present in the white matter (see above). Occasional nerve cells in the amygdala and striatum and nearly all surviving cells within the substantia nigra displayed a diffuse antitau and anti-ubiquitin immunoreactivity.
In patients 1, 2, and 8 occasional nerve cells in the cerebral cortex, hippocampus (dentate gyrus, CAI) amygdala, and striatum showed a weak granular reaction with both anti-tau and anti-ubiquitin but no inclusions were seen. In patients 1, 4, 5, 8, and 11 the frontal and temporal cortical white matter showed a diffuse granularity that was antiubiquitin (and in patients 1 and 5 anti-tau) positive. In patient 3 much fine particulate and thread-like material that was anti-ubiquitin (but not anti-tau) positive was seen in grey (but not white) matter of frontal and temporal cortex. Patients 9 and 10 were entirely unreactive with either anti-tau or antiubiquitin.
In all 12 patients, affected regions of brain showed an increased cerebral cortical GFAP immunoreactivity within reactive astrocytes. Three patterns of gliosis were noted. In one (patients 1, 2, 3, 4, 9, 11, and 12) astrocytosis was mild overall but most prevalent in layers I-II and layer VI, being sparse in layers III-V and in white matter; patient 12 showed similar grey matter changes, but with a heavy white matter gliosis whereas patient 9 showed no white matter changes. In the second (patients 5, 6, 7 The second subgroup (type B) (patients [5] [6] [7] [8] is also characterised by a frontotemporal atrophy but which is defined by a loss of large cortical nerve cells with widespread and abundant gliosis but minimal or no spongiform change. Swollen neurons or inclusions that are both tau and ubiquitin positive are sometimes typically present in some patients and the limbic system and striatum are more seriously damaged.
In the third subgroup (type C) (patients 9-11) the brunt of the pathology is borne by the striatum with (usually) severe limbic involvement but variable cortical and nigral involvement. Immunohistochemistry reveals no significant changes.
In the last subgroup (type D) the atrophy is mostly frontal, with some temporal involvement, characterised by loss of large cortical nerve cells, spongiform change, and mild gliosis; limbic involvement is slight, though nigral damage is severe. Ubiquitinated inclusions are present within the frontal cortex.
CLINICOPATHOLOGICAL RELATIONSHIPS
These four groupings are based on the morphological characteristics of brains retrieved from patients who in life had undergone longitudinal neuropsychological analysis and brain imaging. These clinical data were examined retrospectively and compared with the pathological findings in order to determine any salient clinicopathological relationships.
Demographic features There were no group differences with respect to age of onset, duration of illness, or patient gender (table 1) . However, the presence of a family history of dementia in a first degree relative characterised group A, whereas in group B there was an absence of a family history in most instances. There was a positive family history in one of the three patients in group C, but none in the patient in group D.
Clinical syndromes All patients showed those features associated with dementia of frontal lobe type' (table  2) -that is, profound personality change and social misconduct followed by progressive language impairment. Nevertheless, significant clinical distinctions emerged in group C patients where a stereotyped behaviour represented the dominant clinical feature. Whereas overeating and food fadism occurred in all patients, hyperorality, with the mouthing of inanimate objects, was an early characteristic of group C only. With progression of disease all patients developed neurological signs of akinesia, muscular rigidity, and tremor. However, these were very early and prominent features of group C. The single patient in group D had not had any observable evidence of amyotrophy, but neurophysiological investigations of muscular denervation had not been performed.
SPETfindings
Of the seven patients scanned (table 2), the three from group B had symmetrical reduction of tracer uptake in the frontotemporal lobes. One patient from group A with very rapid decline and modest frontotemporal atrophy had a normal scan. One patient from group C had reported "anterior change in a subcortical distribution" in keeping with the pathological findings. Another patient from group C, with severe ritualistic behaviour, had a normal scan. The single patient from group D had asymmetrical frontal lobe changes on scanning.
Discussion
To date there have been only two other major studies24 and a couple of case reports'516 on the histopathology of these non-Alzheimer forms of dementia.
Brun4 described the pathological changes in the brains of 20 patients suffering from DFT. Four showed a frontal or frontotemporal atrophy characterised histologically by neuronal loss, a moderate or severe gliosis and a fine superficial spongiosus. All cases had swollen (Pick type) cells and inclusions (Pick bodies); a diagnosis of Pick's disease was ascribed. The hippocampus and anmygdala were slightly or moderately affected in these patients. The other 16 patients showed mostly a frontal and anterior temporal degeneration characterised by neuronal loss, slight gliosis, but prominent "spongiosus" of layers I-ILI. Although occasional "swollen cells" were found in four patients, none demonstrated inclusions. The hippocampus and amygdala were slightly affected in a minority (three) of patients; in these a diagnosis of frontal lobe degeneration was given. Knopman et al 2 reported the pathological changes in 14 patients with a condition they termed "dementia lacking distinctive histological features" (DLDH). These showed a mild to moderate atrophy of the frontal lobes in which the histological changes comprised of a vacuolation of the second cortical layer and an astrocytosis that was prominent in the deeper layers in some patients but generalised in others; no senile plaques or neurofibrillary tangles were seen and no swollen neurons or ones containing inclusions were present. The hippocampus was affected in all patients where areas CAl and subiculum showed cell loss and gliosis. The amygdala was inconsistently affected and several patients showed striatal and thalamic gliosis. Although the nucleus basalis and locus caeruleus were mostly unaffected, the substantia nigra was always, though variably, damaged. Five patients also showed hypoglossal degeneration and of these, at least two had developed clinical motor neuron disease. These latter patients appear to conform to other reports67 17 of MND with dementia in which the cortical degeneration, typified by large cell loss, gliosis, and spongiform change, is augmented by severe nigral degeneration and involvement of cranial nuclei and anterior horns. Although in MND and dementia no swollen cells or inclusions are readily observable in cortical regions in routine histological preparations immunohistochemistry'7 has highlighted the presence of inclusions within the dentate gyrus of the hippocampus and lamina 2 of the frontal cortex that seem specific for this condition. Such inclusions are ubiquitin-positive but tau and silver negative'7; findings that set them apart from the inclusions of Pick's disease, within these same cell types, that are both tau and ubiquitin positive, as well as argyrophilic (see here, patients 6, 7, and reference 17). Such 6 and 7) clearly conform, on the basis of the topographical distribution of the brain atrophy, the large cortical cell loss and pronounced gliosis and the presence of tau and ubiquitin positive inclusions within the hippocampus and neocortex, to a diagnosis of typical Pick's disease. The other two patients in this group appeared histologically identical except that the inclusions were not present; whether these should also be classed as Pick's disease remains uncertain, though in the absence of any definitive marker distinguishing such cases with or without Pick bodies it seems safest at present to include all under the rubric of Pick's disease.
Another major concern is to what extent are patients represented by type A or type B (with or without Pick cells) pathologies members of one and the same disease entity? Certainly in the past patients dying with loss of large cortical nerve cells, gliosis, and spongiform change, in the absence of Alzheimer-type lesions or typical Pick cells or inclusions, have been considered to represent variants of the Pick's disease spectrum.'819 While DFT and Pick's disease are clinically very similar and display overlapping neuropsychological profiles6 it is apparent from this present study that distinctions other than the presence or absence of swollen cells and cellular inclusions (see2 4) set them apart. For example, in DFlT a spongiform degeneration of the superficial cortex is a prominent feature and astrocytosis is only mild. A family history of a similar disorder seems to be strongly associated with this pathology (see here and Knopman et al2). In our four patients with "Pick's disease", spongiform change was not prominent though astrocytosis was florid; in most instances (3/4) a family history did not seem to be a feature of this pathology. Hence, there may be good grounds for drawing a clear distinction between DFT and Pick's disease on both pathological and demographic grounds.
Our single patient in group D shows close pathological similarity to those with DFT and motor neuron disease, both in general histological8 and in immunocytochemical'7 features. On clinical examination no signs of amyotrophy were present but neurophysiological evidence of denervation was not sought. The spinal cord was not available for inspection in this patient, though examination of the brainstem showed no obvious cell loss from the hypoglossal nucleus and a normally myelinated corticospinal tract. Nonetheless, the frontal lobe spongiform degeneration8, the hippocampal and nigral changes,8 and the ubiquitin positive inclusions'7 are all indicative of the disease and are quite distinct from patients with DFT (type A) alone. It is possible that this patient had a more chronic form of DFT and MND (duration of illness was at least four years compared with the 2-3 years typically seen8) and that given time clinical signs of MND might well have emerged.
The remaining patients (patients 9-1 1) collected into group C are enigmatic. Their extreme striatal degeneration sets them apart from the other three subgroups and suggests a primary subcortical disorder with variable cortical involvement. Although a family history occurred in patient 1 1, this was not apparent in the other two. The extrapyramidal features and the nigral and striatal involvement in these patients are clinically reminiscent of corticobasal degeneration,20 yet the absence of the characteristic posterior parietal lobe pathology20 and the whorled basophilic inclusions20 within nigral and other subcortical neurons would dictate an alternative diagnosis. At present the nosological status of such patients remains uncertain. Although they bear some pathological resemblance to the other groups, their stereotypic behaviour and the early emergence of extrapyramidal signs (reflecting the predominantly subcortical pathological changes) sets them apart from the more prototypical syndrome of DFT in patients from groups A, B, and D. In these three cases the frontal and temporal cortices may be functionally deafferented rather than primarily structurally impaired.
It appears, therefore, that at present, the clinical entity of DFT is represented by at least four distinctive pathologies; frontal lobe degeneration, Pick's disease, frontal degeneration with MND, and assorted striatocortical degenerations. To what extent these may reflect differing manifestations of a common or a similar aetiological event with the pathological outcome being dictated by a balance of genetic and environmental factors remains uncertain. It is also unclear how these conditions relate to another pathologically similar condition, progressive aphasia,9 21 in which the atrophy again principally affects frontal, temporal, and frontoparietal regions but can be symmetrical or asymmetrical (usually left > right). This condition is also characterised pathologically by a loss of large cortical nerve cells, spongiform change, and gliosis in the absence of swollen cells or neuronal inclusions, even when immunohistochemical procedures are used (Mann, unpublished observations). Moreover, as well as sharing a similar pathological appearance with group A patients, there is likewise a strong familial incidence. It is possible therefore that the clinical syndrome of progressive aphasia may represent an asymmetrical distribution of a more common pathological change so that the linguistic functions of the left dominant cerebral hemisphere are impaired initially and preponderantly. Clearly a definitive answer to the nosological status of these various disorders based on morphological and clinical criteria alone is currently not available; a specific biochemical or molecular marker is necessary before a more rational basis for "lumping" or "splitting" these overlapping pathological conditions can be determined.
